Table 1 Baseline conditions of the two groups before treatment
From: A clinical study of topical treatment for thyroid-associated ophthalmopathy with dry eye syndrome
Indicator | Group A (n = 34) | Group B (n = 31) | P-value |
|---|---|---|---|
Age (years) | 37.26 ± 10.67 | 38.10 ± 11.40 | 0.760 |
Sex—Female | 28 | 23 | 0.309 |
Male | 6 | 8 | |
CAS | 1.35 ± 1.04 | 1.42 ± 1.21 | 0.989 |
Proptosis (mm) | 18.69 ± 2.62 | 18.19 ± 2.77 | 0.460 |
MRD-1 (mm) | 5.06 ± 1.94 | 4.97 ± 1.64 | 0.839 |
MRD-2 (mm) | 5.68 ± 1.27 | 5.52 ± 1.00 | 0.576 |
Vision acuity | 0.93 ± 0.14 | 0.95 ± 0.09 | 0.623 |
IOP (mmHg) | 19.15 ± 3.02 | 18.71 ± 2.51 | 0.529 |
ST (mm) | 8.31 ± 6.28 | 6.40 ± 5.85 | 0.174 |
BUT (s) | 6.17 ± 4.43 | 6.28 ± 3.85 | 0.434 |
OSDI | 19.6 (9.30–43.13) | 21.87 (8.33–43.18) | 0.960 |
FL | 2 (1–5) | 2 (1–2) | 0.255 |